Spermosens reports JUNO-Checked Generation 3 clinical validation study on track
Spermosens AB ("Spermosens" or the "Company") today reports that the clinical validation study of the JUNO-Checked Generation 3 system at the Reproductive Medicine Center (RMC) in Malmö has started and is progressing according to plan. Seven patients have been successfully tested to date. The study started in April 2026, in line with the previously communicated timeline.
As announced recently, the Company completed development of the Generation 3 system and planned to initiate patient recruitment at the RMC in Malmö. The study is now underway, and the first weeks confirm that patient recruitment and clinical routines are progressing as expected, with the JUNO-Checked Generation 3 system performing as intended.
The study includes couples undergoing standard IVF treatment due to unexplained infertility, where semen samples show normal parameters based on currently available sperm analysis methods. Unlike standard semen analysis, JUNO-Checked measures whether sperm cells can bind to the egg, which is essential for fertilization. The aim of the study is to confirm that the Generation 3 system can identify the cause of fertilization failure in cases where standard testing shows no abnormalities. Completion of the study is expected by the end of 2026.
In line with the Company's strategy, Spermosens aims to bring JUNO-Checked to the global market through licensing or partnership agreements with established companies. Successful completion of the clinical validation study is a key step toward commercialization.
Tore Duvold, CEO of Spermosens, comments: "We have started the clinical validation study on schedule, and seven patients have already been tested successfully. This confirms that the study is running as planned and that the Generation 3 system performs well in a clinical setting. We remain on track to complete the study by the end of 2026 and continue our work toward commercial partnerships for JUNO-Checked."
For more information, please contact:
Tore Duvold, CEO
About Spermosens AB
Spermosens AB is a pioneering biotechnology company based in Sweden, focused on advancing fertility diagnostics through science driven solutions. The company develops cutting-edge technologies designed to improve fertility outcomes and streamline treatment pathways for individuals and couples facing infertility. The proprietary product, JUNO-Checked, provides a novel diagnostic approach that enhances precision and evaluations by measuring the sperm-egg binding capacity. JUNO-Checked supports more informed clinical decisions and individualized treatments strategies. Driven by a strong commitment to scientific excellence and patient care, Spermosens collaborates with leading research institutions to deliver transformative fertility diagnostics to the global market. The company's shares are listed on the Spotlight Stock Market under the name SPERM (ISIN code SE0015346424). For more information, see www.spermosens.com.